NL192088C - Cytotoxisch produkt. - Google Patents

Cytotoxisch produkt. Download PDF

Info

Publication number
NL192088C
NL192088C NL7907251A NL7907251A NL192088C NL 192088 C NL192088 C NL 192088C NL 7907251 A NL7907251 A NL 7907251A NL 7907251 A NL7907251 A NL 7907251A NL 192088 C NL192088 C NL 192088C
Authority
NL
Netherlands
Prior art keywords
chain
solution
conjugate
cells
antibody
Prior art date
Application number
NL7907251A
Other languages
English (en)
Dutch (nl)
Other versions
NL7907251A (nl
NL192088B (nl
Original Assignee
Clin Midy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clin Midy filed Critical Clin Midy
Publication of NL7907251A publication Critical patent/NL7907251A/nl
Publication of NL192088B publication Critical patent/NL192088B/xx
Application granted granted Critical
Publication of NL192088C publication Critical patent/NL192088C/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NL7907251A 1978-09-28 1979-09-28 Cytotoxisch produkt. NL192088C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7827838 1978-09-28
FR7827838A FR2437213A1 (fr) 1978-09-28 1978-09-28 Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation

Publications (3)

Publication Number Publication Date
NL7907251A NL7907251A (nl) 1980-04-01
NL192088B NL192088B (nl) 1996-10-01
NL192088C true NL192088C (nl) 1997-02-04

Family

ID=9213144

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7907251A NL192088C (nl) 1978-09-28 1979-09-28 Cytotoxisch produkt.

Country Status (11)

Country Link
US (1) US4340535A (fr)
JP (1) JPS5549321A (fr)
CA (1) CA1188681A (fr)
CH (1) CH647411A5 (fr)
DE (1) DE2939165A1 (fr)
ES (1) ES484591A0 (fr)
FR (1) FR2437213A1 (fr)
GB (1) GB2034324B (fr)
IT (1) IT1207245B (fr)
NL (1) NL192088C (fr)
SE (1) SE446303B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
EP0044167A3 (fr) * 1980-07-14 1982-04-21 The Regents Of The University Of California Agent cytotoxique dirigé par un anticorps
US4440747A (en) * 1980-09-30 1984-04-03 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
JPS57106625A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
SE8102194L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
JPS5874614A (ja) * 1981-10-30 1983-05-06 Teijin Ltd 蛋白複合体及びその製造法
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
FR2522968B1 (fr) * 1982-03-10 1986-03-28 Sanofi Sa Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
WO1983004026A1 (fr) * 1982-05-11 1983-11-24 Genefusion S.A. Agent cytotoxique
US4468382A (en) * 1982-07-15 1984-08-28 New England Medical Center, Inc. Polypeptide-toxin hybrid protein
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
DE3584486D1 (de) * 1984-02-08 1991-11-28 Cetus Corp Toxinkonjugate.
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
CA1314245C (fr) * 1984-05-23 1993-03-09 Franz Jansen Methode de preparation de conjugues formes d'un ionophore carboxylique monovalent associe par une liaison de covalence a une macromolecule et utiles comme agents de potentialisation d'immunotoxines
US4670563A (en) * 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
US6808901B1 (en) * 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
AU585940B2 (en) * 1984-09-25 1989-06-29 Xoma Corporation Lectin immunotoxins
US5185434A (en) * 1985-02-13 1993-02-09 Sanofi Prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
WO1986005098A1 (fr) * 1985-03-04 1986-09-12 Dana-Farber Cancer Institute, Inc. Immunotoxine et procede de production
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US4689311A (en) * 1985-09-30 1987-08-25 Rhode Island Hospital Screening antibodies for capacity to deliver toxin to target cells
US4731439A (en) * 1985-11-22 1988-03-15 Oncogen Snake venom growth arresting peptide
US4962188A (en) * 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
EP0252951A4 (fr) * 1986-01-06 1988-09-07 Univ Melbourne Conjugues technetium-anticorps.
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US5242823A (en) * 1986-03-07 1993-09-07 International Genetic Engineering, Inc. Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen
US4748112A (en) * 1986-03-07 1988-05-31 International Genetic Engineering, Inc. Methods and compositions relating to regression-associated antigens
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
WO1987005515A1 (fr) * 1986-03-20 1987-09-24 Dana-Farber Cancer Institute, Inc. Complexe de lectine et sonde et procede de production
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5395924A (en) * 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US4880935A (en) * 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
FR2601680B1 (fr) * 1986-07-15 1990-06-29 Sanofi Sa Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4871350A (en) * 1986-11-04 1989-10-03 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
US5616122A (en) * 1986-11-04 1997-04-01 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US5158893A (en) * 1986-12-11 1992-10-27 Peralta Cancer Research Institute Methods and compositions for screening carcinomas
US5149528A (en) * 1987-04-10 1992-09-22 Zymogenetics, Inc. Cytotoxic protein from Trichosanthes kirilowii
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
US5591829A (en) * 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US4865841A (en) * 1987-10-23 1989-09-12 Imre Corporation Methods and compositions for transient elimination of humoral immune antibodies
JPH0535249Y2 (fr) * 1988-03-31 1993-09-07
WO1989012624A2 (fr) * 1988-06-14 1989-12-28 Cetus Corporation Agents de couplage et conjugues lies a des disulfures a empechement sterique prepares a partir de tels agents
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
WO1991010742A1 (fr) * 1990-01-16 1991-07-25 Replgien Corporation Anticorps monoclonal specifique de l'epitope non-immunodominant de l'enveloppe proteinique du vih
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
US5578706A (en) * 1993-11-04 1996-11-26 Board Of Regents, The University Of Texas Methods and compositions concerning homogenous immunotoxin preparations
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
US6146628A (en) * 1995-07-11 2000-11-14 Regents Of The University Of Minnesota And Rutgers Biotherapeutic agents comprising recombinant PAP and PAP mutants
ZA9711548B (en) * 1996-12-24 1999-06-23 Res Dev Foundation Ricin inhibitors and methods for use thereof
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
ES2533255T3 (es) 1998-07-13 2015-04-08 Board Of Regents, The University Of Texas System Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
DE69934903T2 (de) * 1998-11-10 2007-10-18 Emory University Mitogene regulatoren
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
GB9926875D0 (en) * 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
AU5003001A (en) 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
CA2437958C (fr) 2001-03-09 2018-10-30 University Of Chicago Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc.gamma. a faible affinite
WO2002079499A1 (fr) 2001-04-02 2002-10-10 Wyeth Le pd-1, recepteur du b7-4, et ses utilisations
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
US20050095627A1 (en) * 2003-09-03 2005-05-05 The Salk Institute For Biological Studies Multiple antigen detection assays and reagents
WO2007025166A2 (fr) * 2005-08-25 2007-03-01 Repair Technologies, Inc. Dispositifs, compositions et methodes de protection et de reparation de cellules et de tissus
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
WO2009141687A1 (fr) * 2008-05-22 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Nouveaux composés optiquement purs pour une efficacité thérapeutique améliorée
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
CN103338782A (zh) 2010-10-04 2013-10-02 国家科学研究中心 包含表面核仁素的多价合成配体和糖胺聚糖的组合物
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
EP3613765A1 (fr) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Anticorps contre le molécule de guidage répulsive b (rgmb)
AU2014241442B2 (en) 2013-03-14 2018-11-15 Regeneron Pharmaceuticals, Inc. Human antibodies to GREM 1
EP3293275B1 (fr) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions et procedes d'identification,d'evaluation, de prevention et de traitement du cancer en utilisant des isoformes pd-l1
EP3757130A1 (fr) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
WO2016094273A1 (fr) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Procédés de régulation à la hausse des réponses immunitaires à l'aide de combinaisons d'agents anti-rgmb et d'agents anti-pd-1
WO2017066561A2 (fr) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
KR20190080825A (ko) 2016-03-21 2019-07-08 다나-파버 캔서 인스티튜트 인크. T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
WO2018044640A1 (fr) 2016-08-29 2018-03-08 Regeneron Pharmaceuticals, Inc. Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020251924A1 (fr) 2019-06-12 2020-12-17 Regeneron Pharmaceuticals, Inc. Anticorps humains dirigés contre la protéine morphogénétique osseuse 6
CN116964088A (zh) 2021-01-25 2023-10-27 里珍纳龙药品有限公司 用于治疗肺动脉高压（pah）的抗pdgf-b抗体和使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
FR2437213A1 (fr) 1980-04-25
JPS5549321A (en) 1980-04-09
GB2034324A (en) 1980-06-04
JPS6220999B2 (fr) 1987-05-11
NL7907251A (nl) 1980-04-01
SE7907994L (sv) 1980-03-29
IT7926118A0 (it) 1979-09-28
CA1188681A (fr) 1985-06-11
US4340535A (en) 1982-07-20
CH647411A5 (fr) 1985-01-31
ES8101384A1 (es) 1980-12-16
SE446303B (sv) 1986-09-01
DE2939165A1 (de) 1980-04-10
IT1207245B (it) 1989-05-17
ES484591A0 (es) 1980-12-16
FR2437213B1 (fr) 1983-05-06
GB2034324B (en) 1984-01-04
NL192088B (nl) 1996-10-01
DE2939165C2 (fr) 1989-08-24

Similar Documents

Publication Publication Date Title
NL192088C (nl) Cytotoxisch produkt.
KR910000029B1 (ko) 효소와 항체의 공유 결합에 의해 결합된 접합체의 제조방법
JPS6221000B2 (fr)
EP0080401B1 (fr) Nouveaux médicaments anticancéreux pour le traitement des leucémies T constitués de la chaine A de la ricine et d'un anticorps monoclonal spécifique
HU188314B (en) Process for production of preparatives suitable for treating of melanoma
JPH02152993A (ja) アンチマーおよびアンチマー複合体
JPH021128B2 (fr)
US4888415A (en) Gelonin immunotoxin
HU210147B (en) Process for producing antibody-drug conjugates and pharmaceutical compositions containing them
EP0255424B1 (fr) Immunotoxines, procédé de préparation et compositions pharmaceutiques en contenant
CA1259920A (fr) Immunotoxine et methode de production
JPH09508389A (ja) フェニルボロン酸錯体
US4582703A (en) Cytotoxic medicament formed from the association of at least one immunotoxin and chloroquin
KR950007215B1 (ko) 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
KR930003333B1 (ko) 탄수화물 단위가 변형된 리보솜을 비활성화시키는 당단백질 성분을 함유하는 지속-작용성 면역독소의 제조방법
JPH0582400B2 (fr)
Vogel Preparation of immunoconjugates using antibody oligosaccharide moieties
US4977280A (en) Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated ionophores
US4767621A (en) Drugs comprising in association at least one immunotoxin and at least one monovalent carboxylic ionophore
EP2049570B1 (fr) Purification d'un anticorps actif de manière bivalente en utilisant un procédé non chromatographique
JP2594803B2 (ja) レクチン複合体及びそれを製造する方法及びプローブ
JPH0780903B2 (ja) 修飾糖タンパク質、当該修飾糖タンパク質の製造方法、当該修飾糖タンパク質を含む免疫毒素および当該免疫毒素を有効成分として含む抗ガン剤組成物
NO168989B (no) Fremgangsmaate for aa oeke loeseligheten av f. eks. immunokonjugatpreparater
EP0283329A1 (fr) Conjugués d'hydrazide d'alcaloide de vinca lie a une immunoglobuline
JPH0428719B2 (fr)

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BT A notification was added to the application dossier and made available to the public
BB A search report has been drawn up
BC A request for examination has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Free format text: 19990928